New institute to lead climate change research
10 April, 2012 by AusBiotechLast week's opening of the Hawkesbury Institute for the Environment at the University of Western Sydney provides Australia with a world-class research institute to tackle the impacts of climate change.
Alchemia partner applies to sell fondaparinux in EU
10 April, 2012 by Dylan Bushell-EmblingDr Reddy's Laboratories has submitted an EU marketing authorisation application covering partner Alchemia's (ASX:ACL) fondaparinux anticoagulant.
Clean Technology Investment Programs open
05 April, 2012 by AusBiotechAusIndustry invites those interested in the new Clean Technology Investment Programs to attend an information session to learn about the programs and how to apply.
Phosphagenics signs Indian skincare licensing deal
05 April, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has signed a deal to license two anti-ageing products formulated for the Indian market to Intas Pharmaceuticals.
Clinuvel set to accelerate phase III study of Scenesse
05 April, 2012 by Dylan Bushell-EmblingClunivel has reached an in-principle agreement with the US Food and Drug Administration to accelerate the phase III trials of Scenesse for the treatment of erythropoietic protoporphyria (EPP).
PolyNovo commences wound treatment trial
05 April, 2012 by Dylan Bushell-EmblingCalzada (ASX:CZD) unit PolyNovo will soon trial its BTM technology as an implant to treat major burns and other full thickness wounds requiring a skin graft.
Changes to IP laws explained
02 April, 2012 by AusBiotechHow the changes in the 'Raising the Bar' Bill to intellectual property legislation will affect life science companies.
Early data show Bionomics' BNC105 effective against tumours
02 April, 2012 by Dylan Bushell-EmblingPreclinical data shows Bionomics' (ASX:BNO) BNC105 compound can be effective in treating platinum-resistant ovarian cancer tumours.
IQnovate to move to ASX
02 April, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (NSX:IQN) will delist from the NSX and move its public share listing to the ASX.
Merged drug developer nears ASX listing
02 April, 2012 by Dylan Bushell-EmblingBioxyne (ASX:BSN), created from the merger of Hunter Immunology and Probiomics (ASX:PCC), is scheduled to list on the ASX in April.
Pharmaxis signs EU distribution deal for Bronchitol
30 March, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has signed a three-year deal with Aravo Healthcare covering distribution of its cystic fibrosis treatment across Europe.
Agenix on track for hepatitis B drug trial
30 March, 2012 by Dylan Bushell-EmblingMelbourne's Agenix (ASX:AGX) expects to be on time with an application to conduct a phase I trial of a prospective hepatitis B treatment in China.
Synchrotron funding to support ongoing research
29 March, 2012 by AusBiotechThe Australian Synchrotron has yesterday secured a $100 million, allowing the Melbourne-based facility to continue research, after the Federal and state governments pledged contributions.
Biota antiviral batters the common cold
29 March, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) has revealed the results of a successful phase IIb trial of its common cold treatment candidate, vapendavir.
Alchemia finalising oncology spin-off
29 March, 2012 by Dylan Bushell-EmblingBrisbane-based Alchemia (ASX:ACL) is in the last stages of planning for the proposed spin-off and IPO of its oncology unit.
